While insulin infusion has been shown to reduce mortality in COVID-19 patients [10], the use of continuous glucose monitoring (CGM) should also improve glucose variability, a phenomenon linked to an increased risk of death in ICU settings, also independently of COVID-19 and diabetes [8,47]. Here, INS is linked to COVID-19.